CSF proteomics reveals changes in myelin and synaptic biology after Spectris treatment.

ABSTRACT:

Introduction

Brain steady-state gamma oscillations evoked using a non-invasive medical device (Spectris) have shown potential clinical benefits in patients with mild-moderate Alzheimer's disease (AD), including reduced functional and cognitive decline, reduced brain volume and myelin loss, and increased brain functional connectivity. We analyzed changes in cerebrospinal fluid (CSF) proteins after Spectris treatment in mild cognitive impairment (MCI) and their relationship to established biological pathways implicated in AD.

Methods

Unbiased proteomic analysis of CSF samples from participants with amyloid-positive MCI (n = 10) was conducted from the FLICKER (NCT03543878) clinical trial. Participants used the Cognito Therapeutics medical device (Spectris), confirmed to

SUBMITTER: Hajos M 

PROVIDER: S-EPMC11812123 | biostudies-literature | 2025 Jan-Mar

REPOSITORIES: biostudies-literature